No matter how you splice it , analyze it or criticize it .. this is hope .. something we have not been able to say in a very very long time for many of our #bladdercancer patients and I am here for it
🔥Breaking News at #ESMO2023!🔥 EV302 is changing the game, unbelievable data (HR=0.45!!!) for metastatic urothelial cancer patients, really an evolution #EV302. Terrific presentation by @tompowles1. 🙌🔬🎗️ @urotoday@OncoAlert@myESMO
🆕 Do not perform immediate cytoreductive nephrectomy in intermediate-risk patients who have an asymptomatic synchronous primary tumour and require systemic therapy.
#RenalCellCarcinoma#EAUguidelines
https://t.co/WQZngHa7Z9
The addition of Talazoparib(PARPi) to enza in CRPC has most effect in BRCA+ve tumors. Effects in the remaining HRR population are marginal or -ve (e.g. ATM). This is largely consistent with previous data for PARPi in CRPC, supporting the ODAC decision on olaparib #ASCO2023